INTRODUCTION {#s1}
============

Coronary heart disease (CHD) has become a main cause of morbidity and mortality worldwide \[[@R1]\]. In 2010, approximately 7,000,000 deaths were reported globally, and in which CHD took up the largest proportion of death causes and years of life lost \[[@R2]\]. Traditional factors, such as hypertension, diabetes and smoking have been proven to contribute to the occurrence and progression of CHD \[[@R3]--[@R5]\]. However, more existed risk factors leading to CHD susceptibility need to be explored. Till now, increasing molecular epidemiological studies have revealed the important role of genetic factors in CHD, and the genetic predisposition is attracting more and more attention \[[@R6], [@R7]\].

MicroRNAs (miRNAs) are small single-stranded non-coding RNA molecules which function in the post-transcriptional regulation of gene expression \[[@R8]\]. Emerging evidence has indicated that the functions of miRNAs appear to be in a variety of fundamental biological processes, involving proliferation, differentiation and stress resistance \[[@R9]--[@R11]\]. In addition, recent studies have shown that miRNAs take part in the regulation of glucose and lipid metabolism, the proliferation of smooth muscle cells and vascular inflammation, which play important roles in the pathogenesis of CHD \[[@R12]--[@R16]\].

By affecting the miRNA maturation and the binding to target mRNAs, single nucleotide polymorphisms (SNPs) located in pre-microRNA (pre-miR) genes may alter the expression levels of a large number of target genes and cause the complex functional consequences \[[@R17]\]. Therefore, functional SNPs in miRNA genes may affect disease susceptibility. Previous studies have confirmed that four common miRNA polymorphisms (rs2910164 G\>C in miR-146a, rs11614913 T\>C in miR-196a2, rs3746444 A\>G in miR-499 and rs71428439 A\>G in miR-149) were associated with several diseases, including various cancers and autoimmune diseases \[[@R18]--[@R21]\]. Recently, these four SNPs were under investigation to uncover the possible genetic predisposing to CHD, but the results were inconsistent. Therefore, we conducted a meta-analysis involving all related publications to assess the association between microRNA polymorphisms and CHD risk.

RESULTS {#s2}
=======

Characteristics of studies {#s2_1}
--------------------------

In total, 285 relevant publications were retrieved according to the search strategy. Firstly, we excluded 254 articles after title reviewing and duplicate screening. Then, 19 studies including 6 reviews, 12 studies not for focus polymorphisms, and 1 study without available information \[[@R22]\] were excluded. Finally, 12 eligible articles (13 studies) published from 2012 to 2016 were selected in the meta-analysis, including ten studies on microRNA-146a rs2910164 G\>C \[[@R23]--[@R32]\], seven studies on microRNA-196a2 rs11614913 T\>C \[[@R23], [@R26], [@R27], [@R29], [@R31], [@R33]\], six publications on microRNA-499 rs3746444 A\>G \[[@R23], [@R25], [@R26], [@R29], [@R31], [@R33]\], and two studies on microRNA-149 rs71428439 A\>G \[[@R29], [@R34]\], respectively. The process of study selection was shown in Figure [1](#F1){ref-type="fig"}. Among the retrieved articles, nine articles \[[@R23], [@R24], [@R26]--[@R30], [@R33], [@R34]\] were written in English and three \[[@R25], [@R31], [@R32]\] in Chinese. Moreover, two of the studies involved Caucasians \[[@R24], [@R30]\], and eleven of them were conducted for Asians. The distribution of genotype was consistent with HWE in all studies but one study for microRNA-146a rs2910164 \[[@R32]\] and two for microRNA-499 rs3746444 polymorphism \[[@R25], [@R31]\]. Detailed characteristics of included studies were shown in Table [1](#T1){ref-type="table"}.

![Flow diagram of the study selection process](oncotarget-08-5692-g001){#F1}

###### Characteristics of case-control studies on microRNA polymorphisms and CHD risk included in the meta-analysis

  First author                     Year   Country/Region   Ethnicity   Source of controls   Case   Control   Genotype distribution   Genotyping methods   Age and sex matched   *P for HWEa*                                                
  -------------------------------- ------ ---------------- ----------- -------------------- ------ --------- ----------------------- -------------------- --------------------- -------------- ----- ----- -------------------- ----------- -------
  microRNA-146a rs2910164 G\>C     CC     GC               GG          CC                   GC     GG                                                                                                                                       
  Sung JH                          2016   Korea            Asian       Hospital             522    535       203                     242                  77                    202            260   73    PCR-RFLP             matched     0.460
  Bastami M                        2016   Iran             Caucasian   NA                   300    300       34                      155                  111                   22             128   150   Taqman               matched     0.454
  Huang SL                         2015   China            Asian       Hospital             722    721       266                     308                  143                   237            348   132   Taqman               matched     0.830
  Xiong XD                         2014   China            Asian       Hospital             295    283       113                     141                  41                    97             125   61    PCR-RFLP             unmatched   0.086
  Prithiksha R                     2014   South Africa     Asian       NA                   106    100       13                      43                   50                    9              46    45    PCR-RFLP             matched     0.569
  Chen CR                          2014   China            Asian       Hospital             919    889       187                     463                  269                   153            435   301   PCR-LDR              unmatched   0.846
  Hamann L                         2014   Germany          Caucasian   Population           206    200       12                      74                   120                   10             73    117   PCR-HRM              unmatched   0.748
  Chen L                           2013   China            Asian       Hospital             658    658       172                     305                  181                   134            330   194   Taqman               matched     0.769
  Yang Y-a                         2012   China            Asian       Population           853    948       272                     392                  165                   271            457   189   Taqman               matched     0.885
  Li L                             2012   China            Asian       Hospital             415    1010      149                     184                  82                    345            455   210   PCR-RFLP             unmatched   0.009
  microRNA-196a2 rs11614913 T\>C   CC     TC               TT          CC                   TC     TT                                                                                                                                       
  Sung JH                          2016   Korea            Korean      Hospital             522    535       107                     236                  179                   108            274   153   PCR-RFLP             matched     0.465
  Huang SL                         2015   China            Asian       Hospital             722    721       147                     381                  190                   156            360   204   Taqman               matched     0.905
  Xiong XD                         2014   China            Asian       Hospital             295    283       78                      131                  86                    68             132   83    PCR-RFLP             unmatched   0.278
  Chen CR                          2014   China            Asian       Hospital             919    889       157                     450                  312                   161            406   322   PCR-LDR              unmatched   0.097
  Zhi H                            2012   China            Asian       Hospital             916    584       155                     470                  291                   98             278   208   PCR-RFLP             matched     0.755
  Yang Y-a                         2012   China            Asian       Population           853    948       163                     463                  202                   217            463   241   Taqman               matched     0.853
  Yang Y-b                         2012   China            Asian       Population           1919   1840      433                     971                  493                   389            921   528   Taqman               matched     0.734
  microRNA-499 rs3746444 G\>A      GG     AG               AA          GG                   AG     AA                                                                                                                                       
  Sung JH                          2016   Korea            Korean      Hospital             522    535       9                       155                  358                   13             168   354   PCR-RFLP             matched     0.182
  Xiong XD                         2014   China            Asian       Hospital             295    283       3                       65                   227                   4              67    212   PCR-RFLP             unmatched   0.616
  Chen CR                          2014   China            Asian       Hospital             919    889       70                      237                  612                   37             246   606   PCR-LDR              unmatched   0.062
  Chen L                           2013   China            Asian       Hospital             658    658       46                      149                  463                   26             158   474   Taqman               matched     0.007
  Zhi H                            2012   China            Asian       Hospital             916    584       86                      201                  629                   21             167   396   PCR-RFLP             matched     0.517
  Yang Y-a                         2012   China            Asian       Population           853    948       28                      210                  589                   28             212   683   Taqman               matched     0.023
  microRNA-149 rs71428439 G\>A     GG     AG               AA          GG                   AG     AA                                                                                                                                       
  Chen CR                          2014   China            Asian       Hospital             919    889       155                     389                  375                   124            381   384   PCR-LDR              unmatched   0.062
  Ding SL                          2013   China            Asian       NA                   289    296       64                      130                  95                    38             126   132   PCR-DNA sequencing   matched     0.360

CHD: coronary heart disease. HWE: Hardy-Weinberg equilibrium. ^a^ HWE in control. NA: not available

Quantitative analysis {#s2_2}
---------------------

Meta-analysis for microRNA-146a rs2910164 G\>C polymorphism {#s2_3}
-----------------------------------------------------------

Ten eligible studies including 4,996 cases and 5,644 controls were included to assess the association between miR-146a rs2910164 polymorphism and CHD risk. The heterogeneity in all genetic models was not significant statistically (*I^2^*\<0.5). So we used the fixed effect model to calculate the ORs and 95% CIs. Overall, an increased CHD risk was detected in all five genetic models (C vs. G: OR = 1.12, 95% CI = 1.06--1.18, *P*\<0.01, *I^2^* = 11.2%; CC vs. GG+GC: OR = 1.19, 95% CI = 1.09--1.30, *P*\<0.01, *I^2^* = 0%; GC + CC vs. GG: OR = 1.12, 95% CI = 1.03--1.23, *P* = 0.012, *I^2^* = 43.6%; CC vs. GG: OR = 1.23, 95% CI = 1.10--1.38, *P*\<0.01, *I^2^* = 9.6%; GC vs. GG: OR = 1.06, 95% CI = 0.97--1.17, *P* = 0.211, *I^2^* = 46.7%) (Figure [2](#F2){ref-type="fig"}, Table [2](#T2){ref-type="table"}). Subgroup analyses of ethnicity disclosed similar results in Asians. In addition, significant associations were observed in subgroup analyses by source of controls and genotyping method (Table [2](#T2){ref-type="table"}). The sensitivity analysis showed that the pooled ORs with corresponding 95%CI were not qualitatively changed by any single study in allelic, recessive, homozygous and heterozygous models, but dominant model (Figure [3](#F3){ref-type="fig"}). Publication bias was estimated by visual inspection of funnel plot and Egger\'s test, and the results revealed no asymmetrical evidence (Figure [4](#F4){ref-type="fig"}). The data of Egger\'s test supported the above results further (C vs. G: *P* = 0.682; CC vs. GG + GC: *P* = 0.283; GC + CC vs. GG: *P* = 0.911; CC vs. GG: *P* = 0.379; GC vs. GG: *P* = 0.877).

![Forests for microRNA-146a rs2910164 G\>C polymorphism and CHD\
**A**. allele model (C vs. G); **B**. recessive model (CC vs. GG + GC); **C**. dominant model (GC + CC vs. GG); **D**. homozygote model (CC vs. GG).](oncotarget-08-5692-g002){#F2}

###### Summary ORs and 95% CI of microRNA-146a rs2910164 polymorphisms and CHD risk

  Locus                 N^\*^   Allele                    Recessive   Dominant                  Homozygote   Heterozygote                                                                              
  --------------------- ------- ------------------------- ----------- ------------------------- ------------ ------------------------ ------ ------------------------- ------ ------------------------ ------
  Total                 10      1.12 (1.06-1.18) \<0.01   11.2        1.19 (1.09-1.30) \<0.01   0            1.12 (1.03-1.23) 0.012   43.6   1.23 (1.10-1.38) \<0.01   9.6    1.06 (0.97-1.17) 0.211   46.7
  Ethnicity                                                                                                                                                                                            
   Asian                8       1.10 (1.04-1.17) \<0.01   0           1.18 (1.08-1.29) \<0.01   0            1.09 (0.99-1.20) 0.083   22.6   1.20 (1.07-1.35) \<0.01   0      1.03(0.93-1.14) 0.631    30.5
   Caucasian            2       1.25 (0.88-1.77) 0.205    66.5        1.47 (0.92-2.35) 0.108    0            1.33 (0.80-2.21) 0.277   75.0   1.74 (1.07-2.84) 0.025    13.4   1.29 (0.79-2.11) 0.312   70.9
  Source of controls                                                                                                                                                                                   
   Population           2       1.08 (0.95-1.22) 0.247    0           1.17 (0.96-1.42) 0.130    0            1.04 (0.85-1.27) 0.733   0      1.15 (0.89-1.49) 0.281    0      0.98 (0.80-1.22) 0.883   0
   Hospital             6       1.11 (1.04-1.19) \<0.01   0           1.18 (1.07-1.31) \<0.01   0            1.11 (0.99-1.24) 0.067   40.9   1.22 (1.07-1.39) \<0.01   23.8   1.04 (0.93-1.17) 0.470   47.0
  Method                                                                                                                                                                                               
   Taqman               4       1.15 (1.03-1.29) 0.017    50.0        1.24 (1.10-1.41) \<0.01   0            1.14 (0.90-1.43) 0.281   67.3   1.23 (1.05-1.44) 0.012    41.9   1.05 (0.82-1.36) 0.698   69.9
   PCR-RFLP             4       1.07 (0.97-1.19) 0.177    0           1.10 (0.94-1.28) 0.227    0            1.09 (0.91-1.31) 0.347   45.0   1.16 (0.94-1.43) 0.165    22.9   1.05 (0.87-1.28) 0.598   44.2
  Age and sex matched   6       1.11 (1.03-1.19) \<0.01   35.3        1.21 (1.08-1.35) \<0.01   0            1.08 (0.90-1.29) 0.420   52.7   1.18 (1.02-1.37) 0.024    25.0   1.00 (0.83-1.22) 0.981   54.1
  Controls in HWE       9       1.13 (1.06-1.20) \<0.01   17.0        1.21 (1.10-1.33) \<0.01   0            1.13 (1.03-1.25) 0.012   49.4   1.25 (1.11-1.41) \<0.01   15.7   1.07 (0.92-1.25) 0.396   52.5

^\*^ Numbers of comparisons. PCR-RFLP: polymerase chain reaction-based restriction fragment length polymorphism. HWE: Hardy-Weinberg equilibrium.

![Sensitivity analyses for microRNA-146a rs2910164 G\>C polymorphism and CHD\
**A**. allele model (C vs. G); **B**. recessive model (CC vs. GG + GC); **C**. dominant model (GC + CC vs. GG); **D**. homozygote model (CC vs. GG).](oncotarget-08-5692-g003){#F3}

![Funnel plots for microRNA-146a rs2910164 G\>C polymorphism and CHD\
**A**. allele model (C vs. G); **B**. recessive model (CC vs. GG + GC); **C**. dominant model (GC + CC vs. GG); **D**. homozygote model (CC vs. GG).](oncotarget-08-5692-g004){#F4}

Meta-analysis for microRNA-196a2 rs11614913 T\>C polymorphism {#s2_4}
-------------------------------------------------------------

Seven original studies involving 6,668 cases and 6,335 controls were analyzed for miRNA-196a2 rs11614913 T\>C polymorphism and CHD susceptibility. In the overall analysis, significant associations were found in the dominant model (TC + CC vs. TT: OR = 1.08, 95%CI = 1.00--1.17, *P* = 0.046, *I^2^*= 27.3%) and heterozygous model (TC vs. TT: OR = 1.10, 95%CI = 1.01--1.19, *P* = 0.029, *I^2^*= 40%) (Figure [5](#F5){ref-type="fig"}, Table [3](#T3){ref-type="table"}). In the stratified analysis, significant results were observed in group with population-based controls as well as genotyping method of Taqman (Table [3](#T3){ref-type="table"}). Publication bias analyses were performed, and the shapes of funnel plots ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}) were consistent with the Egger\'s test approved (C vs. T: *P* = 0.262; CC vs. TT + TC: *P* = 0.650; TC + CC vs. TT: *P* = 0.226; CC vs. TT: *P* = 0.220; TC vs. TT: *P* = 0.292). However, when sensitivity analysis was performed, some changes of the pooled ORs were detected under both dominant and heterozygous models ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

![Forests for microRNA-196a2 rs11614913 T\>C polymorphism and CHD\
**A**. dominant model (TC + CC vs. TT); **B**. heterozygote model (TC vs. TT).](oncotarget-08-5692-g005){#F5}

###### Summary ORs and 95% CI of microRNA-196a2 rs11614913 polymorphisms and CHD risk

  Locus                 N^\*^   Allele                   Recessive   Dominant                 Homozygote   Heterozygote                                                                             
  --------------------- ------- ------------------------ ----------- ------------------------ ------------ ------------------------ ------ ------------------------ ------ ------------------------ ------
  Total                 7       1.03 (0.98-1.09) 0.252   0           0.99 (0.90-1.08) 0.801   6.0          1.08 (1.00-1.17) 0.046   27.3   1.05 (0.95-1.16) 0.370   0      1.10 (1.01-1.19) 0.029   40.0
  Source of controls                                                                                                                                                                                
   Population           2       1.03 (0.91-1.17) 0.615   60.3        0.95 (0.69-1.30) 0.736   81.3         1.13 (1.00-1.28) 0.042   0      1.05 (0.80-1.39) 0.711   64.8   1.15 (1.01-1.30) 0.032   0
   Hospital             5       1.02 (0.95-1.09) 0.671   0           0.98 (0.87-1.11) 0.793   0            1.05 (0.94-1.17) 0.389   44.8   1.01 (0.88-1.17) 0.863   0      1.04 (0.87-1.24) 0.666   55.4
  Method                                                                                                                                                                                            
   Taqman               3       1.04 (0.97-1.11) 0.242   25.3        0.95 (0.78-1.16) 0.604   63.9         1.13 (1.01-1.25) 0.030   0      1.08 (0.94-1.23) 0.299   34.2   1.15 (1.02-1.28) 0.017   0
   PCR-RFLP             3       1.01 (0.91-1.12) 0.847   30.4        1.04 (0.87-1.25) 0.661   0            0.98 (0.74-1.29) 0.867   68.5   1.02 (0.83-1.25) 0.874   0      0.95 (0.69-1.32) 0.775   72.4
  Age and sex matched   5       1.03 (0.97-1.09) 0.315   30.4        0.99 (0.90-1.09) 0.825   28.9         1.07 (0.93-1.22) 0.342   50.4   1.05 (0.94-1.18) 0.387   18.0   1.08 (0.93-1.26) 0.316   57.3

^\*^ Numbers of comparisons. PCR-RFLP: polymerase chain reaction-based restriction fragment length polymorphism.

Meta-analysis for microRNA-499 rs3746444 A\>G polymorphism {#s2_5}
----------------------------------------------------------

Six relevant studies comprising 4,163 patients and 3,897 controls were included in the meta-analysis for miRNA-499 rs3746444 A\>G polymorphism and CHD risk. The pooled analyses indicated that this polymorphism was associated with an increased risk of CHD in three genetic models (G vs. A: OR = 1.11, 95% CI = 1.02--1.20, *P* = 0.015, *I^2^* = 17.8%; GG vs. AA + AG: OR = 1.55, 95% CI = 1.07--2.27, *P* = 0.022, *I^2^*= 58.1%; GG vs. AA: OR = 1.54, 95% CI = 1.08--2.20, *P* = 0.017, *I^2^*= 52.6%) (Figure [6](#F6){ref-type="fig"}, Table [4](#T4){ref-type="table"}). Subsequent subgroup analyses revealed similar results in the hospital-based control group, genotyping method of Taqman group as well as age and sex matched group (Table [4](#T4){ref-type="table"}). No significant publication bias was found, indicating that the meta-analysis results are reliable (G vs. A: *P* = 0.092; GG vs. AA + AG: *P* = 0.156; AG + GG vs. AA: *P* = 0.182; GG vs. AA: *P* = 0.198; AG vs. AA: *P* = 0.821) ([Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). However, further sensitivity analysis revealed that omission of each study made some significant differences on the findings ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}).

![Forests for microRNA-499 rs3746444 A\>G polymorphism and CHD\
**A**. allele model (G vs. A); **B**. recessive model (GG vs. AA + AG); **C**. homozygote model (GG vs. AA).](oncotarget-08-5692-g006){#F6}

###### Summary ORs and 95% CI of microRNA-499 rs3746444 polymorphisms and CHD risk

  Locus                 N^\*^   Allele                   Recessive   Dominant                 Homozygote   Heterozygote                                                                           
  --------------------- ------- ------------------------ ----------- ------------------------ ------------ ------------------------ ---- ------------------------ ------ ------------------------ ------
  Total                 6       1.11 (1.02-1.20) 0.015   17.8        1.55 (1.07-2.27) 0.022   58.1         1.03 (0.94-1.13) 0.545   0    1.54 (1.08-2.20) 0.017   52.6   0.95 (0.85-1.05) 0.275   21.8
  Source of controls                                                                                                                                                                              
   Population           1       1.13 (0.94-1.36) 0.199   NA          1.12 (0.66-1.91) 0.676   NA           1.15 (0.93-1.42) 0.193   NA   1.16 (0.68-1.98) 0.588   NA     1.15 (0.92-1.43) 0.218   NA
   Hospital             5       1.10 (1.01-1.21) 0.039   33.7        1.68 (1.11-2.55) 0.014   55.9         1.00 (0.90-1.12) 0.990   0    1.65 (1.10-2.46) 0.015   52.4   0.90 (0.80-1.01) 0.061   0
  Method                                                                                                                                                                                          
   Taqman               2       1.15 (1.01-1.32) 0.042   0           1.46 (1.02-2.10) 0.038   42.7         1.12 (0.96-1.31) 0.156   0    1.48 (1.03-2.12) 0.034   30.1   1.07 (0.90-1.26) 0.446   0.8
   PCR-RFLP             3       1.03 (0.90-1.17) 0.693   48.8        1.24 (0.42-3.66) 0.693   77.9         0.93 (0.79-1.08) 0.330   0    1.20 (0.42-3.39) 0.737   76.1   0.84 (0.71-0.99) 0.033   0
  Age and sex matched   4       1.10 (1.00-1.22) 0.052   27.5        1.51 (0.89-2.57) 0.127   71.1         1.03 (0.92-1.15) 0.631   0    1.49 (0.91-2.45) 0.113   66.5   0.94 (0.79-1.12) 0.493   52.7
  Controls in HWE       4       1.08 (0.98-1.20) 0.132   45.2        1.55 (0.86-2.79) 0.144   66.9         0.98 (0.87-1.11) 0.744   0    1.51 (0.85-2.66) 0.159   64.3   0.88 (0.77-1.00) 0.050   0

^\*^ Numbers of comparisons. PCR-RFLP: polymerase chain reaction-based restriction fragment length polymorphism. HWE: Hardy-Weinberg equilibrium. NA: not available.

Meta-analysis for microRNA-149 rs71428439 A\>G polymorphism {#s2_6}
-----------------------------------------------------------

A total of 2 studies with 1,208 cases and 1,185 controls were selected in the meta-analysis. This polymorphism was not found to be significantly associated with CHD risk in all five models (G vs. A: OR = 1.30, 95% CI = 0.94--1.79, *P* = 0.107, *I^2^* = 82.1%; GG vs. AA+AG: OR = 1.50, 95% CI = 0.98--2.27, *P* = 0.059, *I^2^* = 64.2%; AG + GG vs. AA: OR = 1.31, 95% CI = 0.89--1.93, *P* = 0.169, *I^2^* = 75.8%; GG vs. AA: OR = 1.67, 95% CI = 0.93--3.01, *P* = 0.086, *I^2^* = 78.1%; AG vs. AA: OR = 1.18, 95% CI = 0.87--1.59, *P* = 0.281, *I^2^* = 55.6%).

DISCUSSION {#s3}
==========

Coronary heart disease is the most common cause of morbidity and mortality in most regions worldwide. Although we have conducted some major advances in the understanding of cardiovascular disease in more recent decades, detailed pathogenesis of CHD remain to be explored. Nowadays, the association between polymorphisms of microRNAs and CHD risk is drawing more and more attention.

In the current meta-analysis, we comprehensively investigated the associations between microRNA-146a rs2910164 G\>C, microRNA-196a2 rs11614913 T\>C, microRNA-499 rs3746444 A\>G and microRNA-149 rs71428439 A\>G polymorphisms and CHD risk according to thirteen included case-control studies, consisting of 8,120 patients and 8,364 controls. Overall, significant increased risks of CHD were observed for microRNA-146a rs2910164, microRNA-196a2 rs11614913 and microRNA-499 rs3746444, but not miRNA-149 rs71428439.

As for miRNA-146a rs2910164 G\>C, this is the latest and largest meta-analysis investigated the association with CHD risk. Compared with the previous meta-analysis with four studies including 2506 subjects \[[@R35]\], we found that the significant association existed in recessive model, as well as no association in heterozygous model. The advantages of our analysis are as follows. First, our meta-analysis had much larger sample size: we added another six recent studies involving 8,134 subjects which were not part of the previous meta-analysis \[[@R23], [@R24], [@R27], [@R29], [@R31], [@R32]\]. Second, sensitivity analyses showed that our results were statistically robust in four genetic models. Also, no significant publication bias was detected in our meta-analysis. Third, we performed a more comprehensive subgroup analyses. Stratification by ethnicity showed an increased CHD risk for microRNA-146a rs2910164 G\>C polymorphism in Asians. Furthermore, similar increased results were observed in the group with genotyping method of Taqman, rather than PCR-RFLP. It revealed that Taqman was a more useful genotyping method to improve the accuracy of experiment.

To the best of our knowledge, this is the first meta-analysis assessing the association of miRNA-196a2 rs11614913 T\>C, miRNA-499 rs3746444 A\>G, and miRNA-149 rs71428439 A\>G polymorphisms with CHD susceptibility. Interestingly, by increasing the sample size, the results of the combined analysis revealed a significant association with CHD risk for microRNA-196a2 rs11614913, even though no association was found in each single original study. How can we explain the association of miRNA-196a2 rs11614913 with CHD susceptibility? First, the miRNA-196a2 rs11614913 polymorphism involved a T to C nucleotide substitution and situated in the 3p strand of mature miRNA regions, which might affect both pre-miRNA maturation of 5p and 3p miRNAs and the interacting of target mRNAs to 3p mature miRNAs \[[@R36]\]. Second, it has been reported that miR-196a2 was closely associated with the regulation of annexin A1 (ANXA1) \[[@R37]\]. As an important modulator in atherosclerosis, ANXA1 can inhibit not only the monocyte adhesion to endothelium but also the expression of inflammatory enzymes, such as inducible cyclooxygenase 2 (COX-2) and phospholipase A2 \[[@R38], [@R39]\]. Additionally, the predicted targets of miR-196a2 included hundreds of genes ( <http://www.targetscan.org>). There also existed the possibility that other targets of miR-196a2 might play some roles in the development of CHD, despite it was unknown by far.

Our meta-analysis had several limitations. First of all, the ethnicity of most subjects was Asian in the current study and this restricted the general application of the results to other populations. Second, only articles published in English or Chinese were selected, potentially causing a language bias. Third, in the sensitivity analysis for miRNA-196a2 rs11614913 T\>C and miRNA-499 rs3746444 A\>G, we found that omission of each study made some significant differences on the results. Although it may be explained by the small number of studies included, the caution should be indicated when interpreting the association of these two miRNA polymorphisms with CHD. Third, the heterogeneity existed in our meta-analysis for miRNA-499 rs3746444 A\>G and microRNA-149 rs71428439 A\>G. For rs3746444, although subgroup and sensitivity analyses were performed, unfortunately, we have not found the sources of heterogeneity. Also, as for rs71428439, only two included studies were too small to analyze the sources of heterogeneity. Fourth, CHD is both multi-factorial disease influenced by genetic and environmental factors. However, in our current meta-analysis, the inter-gene and gene-environment interactions could not be conducted owing to the data deficiency. Last but not the least, genetic epidemiological studies show different genetic variants can predispose to different subtypes of CHD \[[@R40]--[@R42]\]. So subtypes of CHD, such as myocardial infarction, acute coronary syndrome and stable angina should be further analyzed. Unfortunately, we could not assess the difference among these subtypes of CHD due to insufficient statistical data in the literature.

In conclusion, the current meta-analysis demonstrated that three functional polymorphisms of microRNA-146a rs2910164 G\>C, microRNA-196a2 rs11614913 T\>C and microRNA-499 rs3746444 A\>G might take important part in the development of CHD. Considering the limitations in the current meta-analysis, our results should be interpreted with caution. More eligible studies with rigorous design are needed to confirm the association of above polymorphisms in miRNA and CHD risk in the future.

MATERIALS AND METHODS {#s4}
=====================

Search strategy {#s4_1}
---------------

We searched four electronic databases (Pubmed, Embase, CNKI and Wanfang) for articles written in English or Chinese published prior to August 31, 2016. The following medical subject heading terms were used: (microRNA OR miRNA) AND (myocardial infarction OR ischemic heart disease OR ischaemic heart disease OR coronary heart disease OR coronary artery disease OR coronary syndrome OR coronary stenosis OR coronary disease OR cardiovascular disease OR CAD OR CHD OR MI) AND (genotype OR gene OR allele OR polymorphism OR variant OR SNP).

Study selection {#s4_2}
---------------

All selected studies had to meet the following criteria: (1) published studies based on case-control design assessing the association of rs2910164 G\>C in miR-146a, rs11614913 T\>C in miR-196a2, rs3746444 A\>G in miR-499 and rs71428439 A\>G in miR-149 with CHD risk; (2) availability of allele or genotype frequency for calculating odds radio (OR) and their 95% confidence interval (CI). Studies were excluded if they investigated the progression, severity, phenotype modification, response to treatment, survival or family based studies. Moreover, meeting abstracts, case reports, editorials, review articles and non-English and non-Chinese articles were also excluded. For duplicate publications, the one with more complete design or larger sample size was finally selected.

Data extraction {#s4_3}
---------------

The two of the authors independently extracted the data from each relevant study including the first author, publication year, study country/region, ethnicity of participants (such as Asian or Caucasian), sources of controls, genotyping method, case-control matched status, HWE status of controls and number of genotypes in CHD cases and controls. Disagreements were reconciled through group discussion. The Hardy-Weinberg equilibrium (HWE) was calculated based on the genotypes of the controls.

Statistical analysis {#s4_4}
--------------------

Heterogeneity among studies was examined with the *I^2^* statistic and *I^2^*\>50% indicates significant heterogeneity between the studies. Based on the test of heterogeneity, a pooled OR was calculated by using fixed or random effect model, along with the 95% CI to measure the strength of the genetic association. For the microRNA-146a rs2910164 G\>C polymorphism, the pooled ORs were obtained for the allele contrast (C vs. G), recessive model (CC vs. GG+GC), dominant model (GC+CC vs. GG), homozygous (co-dominant) model (CC vs. GG) and heterozygous (co-dominant) model (GC vs. GG). Similar genetic models were also assessed for microRNA-196a2 rs11614913 T\>C, microRNA-499 rs3746444 A\>G and microRNA-149 rs71428439 A\>G variants. Subgroup analyses of ethnicity, source of controls, genotyping methods, case-control matched status and HWE status of controls were also submitted to statistical testing. In order to evaluate the stability of the results, sensitivity analysis was used, which meant omitting one study at a time, and then compared to show whether a significant difference existed between the former and the latter results. Publication bias was examined by the visual inspection of funnel plot, and Egger\'s regression test. Data were analyzed and processed using Stata 12.0 (Stata Corporation, College Station, TX, USA). *P*\<0.05 was considered statistically significant.
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